Go to content
UR Home

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

Brüggemann, C., Kirchberger, M. C., Goldinger, S. M., Weide, B., Konrad, A., Erdmann, M., Schadendorf, D., Croner, R. S., Krähenbühl, L., Kähler, K. C., Hafner, C., Leisgang, W., Kiesewetter, F., Dummer, R., Schuler, G., Stürzl, M. and Heinzerling, L. (2017) Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. Journal of Cancer Research and Clinical Oncology 143 (10), pp. 1977-1984.

Full text not available from this repository.

at publisher (via DOI)

Other URL: http://doi.org/10.1007/s00432-017-2450-2


Abstract

Introduction PD-L1 is established as a predictive marker for therapy of non-small cell lung cancer with pembrolizumab. Furthermore, PD-L1 positive melanoma has shown more favorable outcomes when treated with anti-PD1 antibodies and dacarbazine compared to PD-L1 negative melanoma. However, the role of PD-L1 expression with regard to response to checkpoint inhibition with anti-CTLA-4 is not clear, ...

plus


Export bibliographical data



Item type:Article
Date:2017
Institutions:Medicine > Lehrstuhl für Dermatologie und Venerologie
Identification Number:
ValueType
10.1007/s00432-017-2450-2DOI
Keywords:PARAFFIN-EMBEDDED TISSUE; METASTATIC MELANOMA; TUMOR MICROENVIRONMENT; CANCER-IMMUNOTHERAPY; BLOCKADE; EXPRESSION; SURVIVAL; LYMPHOCYTE; THERAPIES; PEMBROLIZUMAB; PD-L1; Ipilimumab; Predictive marker; Prognostic marker; Checkpoint inhibitors; Melanoma; Biomarker
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Yes
Item ID:39754
Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons